论文部分内容阅读
目的比较埃索美拉唑与奥美拉唑在胃溃疡治疗中的应用价值。方法选取贵港市覃塘区石卡中心卫生院2013年10月—2015年8月收治的胃溃疡患者80例,按照数字抽取法分为观察组和对照组,各40例。观察组应用埃索美拉唑治疗,对照组应用奥美拉唑治疗。比较两组患者治疗前后症状积分,临床治疗效果及幽门螺杆菌(Hp)根除率,并对比两组患者治疗前及治疗后5、7d的血清白介素8(IL-8)、血小板压积(PCT)、肿瘤坏死因子α(TNF-α)水平变化情况及不良反应发生情况。结果治疗前两组患者症状积分比较,差异无统计学意义(P>0.05)。治疗后两组患者症状积分均低于治疗前(P<0.05);且观察组症状积分低于对照组(P<0.05)。观察组治疗总有效率及Hp根除率高于对照组(P<0.05)。治疗前两组患者血清IL-8、PCT、TNF-α水平比较,差异无统计学意义(P>0.05);治疗后5、7d,观察组IL-8、PCT、TNF-α水平均低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论埃索美拉唑治疗胃溃疡较奥美拉唑效果显著,临床应用价值更高。
Objective To compare the value of esomeprazole and omeprazole in the treatment of gastric ulcer. Methods Eighty patients with gastric ulcer admitted to Shiqian Central Hospital of Qitang District from October 2013 to August 2015 were selected and divided into observation group and control group according to digital extraction method, 40 cases in each group. The observation group was treated with esomeprazole and the control group was treated with omeprazole. Symptom scores, clinical outcomes and H. pylori eradication rates were compared between the two groups before and after treatment. Serum levels of interleukin 8 (IL-8), platelet pressure (PCT) ), Tumor necrosis factor α (TNF-α) levels and the occurrence of adverse reactions. Results Before treatment, symptom scores of the two groups were not significantly different (P> 0.05). After treatment, symptom scores of both groups were lower than those before treatment (P <0.05); symptom score of observation group was lower than that of control group (P <0.05). Observation group, the total effective rate and Hp eradication rate was higher than the control group (P <0.05). The serum levels of IL-8, PCT and TNF-α in the two groups before treatment were not significantly different (P> 0.05). At 5 and 7 days after treatment, the levels of IL-8, PCT and TNF- Control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Esomeprazole is more effective than omeprazole in the treatment of gastric ulcer and has higher clinical value.